UCB FY Bimzelx sales EUR2.23B, est. EUR1.98B
TL;DR
UCB's Bimzelx sales reached €2.23B in FY 2025, surpassing the €1.98B estimate, driven by strong U.S. adoption and favorable programs. The drug is key to revenue growth, with a peak target over €4B, though future performance may face competitive and reimbursement challenges.
Tags
UCB FY Bimzelx sales EUR2.23B, est. EUR1.98B
UCB Reports Strong Performance for Bimzelx in Fiscal 2025
UCB SA (Euronext: UCB) reported full-year 2025 sales of Bimzelx (bimekizumab) at €2.23 billion, exceeding the estimated range of €1.98 billion previously communicated by the company[^NUMBER]. The drug, a key growth driver for UCB, contributed significantly to the firm's overall revenue, which is projected to reach at least €7 billion for 2025.
The outperformance in Bimzelx sales was supported by accelerated adoption in the U.S., where expanded access in the first half of 2025 led to a faster conversion of prescriptions to paid scripts. However, the company noted that non-recurring items in the first half of 2025, such as exceptional performance tied to the drug's launch phase, may not be fully replicable in subsequent periods.
UCB's guidance for 2025 revenue and adjusted EBITDA (at least 30% margin) remains intact, with Bimzelx positioned to continue driving growth as it approaches its peak sales target of over €4 billion. The drug's performance also benefited from favorable dynamics under the U.S. IRA and 340B programs, which impacted pricing and reimbursement across key indications.
The strong sales growth contributed to operating cash flow of €711 million as of June 2025, reflecting improved gross margins and operating leverage. UCB's net financial debt stood at €1.267 billion as of June 2025, with a debt-to-adjusted EBITDA ratio of 0.7x, underscoring the company's disciplined capital management.
While Bimzelx's 2025 results exceeded expectations, UCB emphasized that sustained growth will depend on maintaining market share and navigating potential headwinds, such as competitive dynamics and evolving reimbursement frameworks. The company remains focused on leveraging its biopharma portfolio to deliver long-term value for stakeholders.
(https://www.ucb.com/investors/performance): Financial data and guidance sourced from UCB's investor relations materials (https://www.ucb.com/investors/performance).
